Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma | Micallef et al. Journal of Hematology Oncology 2010 3 13 http www.jhoonline.Org content 3 1 13 JOURNAL OF HEMATOLOGY ONCOLOGY REVIEW Open Access Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma Johann Micallef 1 2 Moyez Dharsee3 Jian Chen3 Suzanne Ackloo3 Ken Evans3 Luqui Qiu4 and Hong Chang 1 2 Abstract Multiple myeloma MM is the second most common hematological malignancy in adults. It is characterized by clonal proliferation of terminally differentiated B lymphocytes and over-production of monoclonal immunoglobulins. Recurrent genomic aberrations have been identified to contribute to the aggressiveness of this cancer. Despite a wealth of knowledge describing the molecular biology of MM as well as significant advances in therapeutics this disease remains fatal. The identification of biomarkers especially through the use of mass spectrometry however holds great promise to increasing our understanding of this disease. In particular novel biomarkers will help in the diagnosis prognosis and therapeutic stratification of MM. To date results from mass spectrometry studies of MM have provided valuable information with regards to MM diagnosis and response to therapy. In addition mass spectrometry was employed to study relevant signaling pathways activated in MM. This review will focus on how mass spectrometry has been applied to increase our understanding of MM. Multiple Myeloma Multiple myeloma MM the second most common blood cancer in adults is a neoplasm of terminally differentiated B-cells characterized by clonal expansion of malignant plasma cells in the bone marrow. The most common symptoms associated with MM include lytic bone lesions renal failure calcium dysregulation anemia and susceptibility to infections. The median age at diagnosis of MM is 62 years for men and 61 years for women with less than 2 of those diagnosed at an age less than 40 years. The incidence of MM in the USA is more common among men 7.1 .
